ANIK
Anika Therapeutics Inc.

640
Mkt Cap
$135.99M
Volume
17,625.00
52W High
$18.37
52W Low
$7.87
PE Ratio
-4.14
ANIK Fundamentals
Price
$9.48
Prev Close
$9.43
Open
$9.50
50D MA
$9.54
Beta
0.93
Avg. Volume
171,095.21
EPS (Annual)
-$3.83
P/B
0.93
Rev/Employee
$416,343.75
Loading...
Loading...
News
all
press releases
Acadian Asset Management LLC Boosts Position in Anika Therapeutics Inc. $ANIK
Acadian Asset Management LLC lifted its position in shares of Anika Therapeutics Inc. (NASDAQ:ANIK - Free Report) by 6.7% in the second quarter, according to its most recent filing with the...
MarketBeat·20d ago
News Placeholder
More News
News Placeholder
Anika Therapeutics (NASDAQ:ANIK) Upgraded at Wall Street Zen
Wall Street Zen upgraded Anika Therapeutics from a "hold" rating to a "buy" rating in a research report on Saturday...
MarketBeat·25d ago
News Placeholder
Barrington Research Forecasts Strong Price Appreciation for Anika Therapeutics (NASDAQ:ANIK) Stock
Barrington Research increased their price target on shares of Anika Therapeutics from $15.00 to $16.00 and gave the company an "outperform" rating in a research note on Thursday...
MarketBeat·26d ago
News Placeholder
Anika Therapeutics (NASDAQ:ANIK) Releases Quarterly Earnings Results, Misses Estimates By $0.19 EPS
Anika Therapeutics (NASDAQ:ANIK - Get Free Report) issued its quarterly earnings results on Wednesday. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, missing the...
MarketBeat·27d ago
News Placeholder
Anika Therapeutics (ANIK) Q3 Earnings and Revenues Top Estimates
Anika (ANIK) delivered earnings and revenue surprises of +100.00% and +0.06%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·28d ago
News Placeholder
Arcturus Therapeutics (ARCT) Surges 8.7%: Is This an Indication of Further Gains?
Arcturus Therapeutics (ARCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks·3mo ago
News Placeholder
Wall Street Analysts See a 98.59% Upside in Anika (ANIK): Can the Stock Really Move This High?
The consensus price target hints at a 98.6% upside potential for Anika (ANIK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks·3mo ago
News Placeholder
Anika (ANIK) Upgraded to Buy: Here's What You Should Know
Anika (ANIK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks·3mo ago
News Placeholder
Anika Therapeutics (ANIK) Reports Q2 Loss, Tops Revenue Estimates
Anika (ANIK) delivered earnings and revenue surprises of 0.00% and +4.32%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago
News Placeholder
uniQure (QURE) Reports Q2 Loss, Misses Revenue Estimates
uniQure (QURE) delivered earnings and revenue surprises of +22.47% and -26.23%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago

Latest ANIK News

View

Advertisement|Remove ads.

Advertisement|Remove ads.